Supporting Korean Biomanufacturing
Clinical & commercial manufacturing
ENTRI supports analytical and process development, drug substance (DS), drug product (DP), manufacturing, and on-site Quality Control, including:
Biologics: ADCs, bioconjugates and mAbs.
Cell and gene therapies: CAR T-cell therapies, iPSC-based products, extracellular vesicles (EVs).
RNA-based products: mRNA-LNPs.
Drug-device combination products. Other product types may also be supported, subject to facility fit.
World-class infrastructure
ENTRI offers cGMP cleanrooms, wet labs (PC2 compliant), and office spaces.
Spread over four levels and more than 7,000 m2 (75,000 ft2), ENTRI adheres to TGA and PIC/S-aligned manufacturing standards within quality-controlled environments.
ENTRI offers scalable manufacturing infrastructure and supports multiple modalities, which adapt to suit tenants’ needs.
Infrastructure and facilities, including cGMP cleanrooms, wet labs, and office spaces, are licencible for tenants’ exclusive use.
Navigate ENTRI
Innovation and Collaboration space
Non-CDMO Model
Enhanced Control: Maintain full oversight of critical production processes and manufacturing intellectual property.
Compliance: Facilities meet cGMP and global regulatory standards.
Flexibility: Easily adapt to changing production demands, schedules, and timelines.
Dedicated Capacity: Secure guaranteed manufacturing capacity to use across pipeline assets.
Clinical Trials Network
ENTRI can accelerate speed to clinic.
Access state-of-the-art adult and paediatric clinical trial units through TRI’s partners, and within the expansive Queensland’s clinical trial network.
Read more about:
Retain IP & Control
ENTRI offers a disciplined alternative to a CDMO model. Companies that choose to base their operations at ENTRI retain the intellectual property rights to their manufacturing processes and products.
Tenants are responsible for all regulatory approvals, including those from the TGA.
Australia offers pharmaceutical patients for up to 25 years, which protects the IP rights of both the creators and owners.